A Trial Comparing the Glycaemic Control of Levemir® Administered Once Daily According to Two Insulin Detemir Titration Algorithms After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment With or Without Other Anti-diabetic Drugs (OADs)
A Trial Comparing the Glycaemic Control of Levemir® Administered Once Daily According to Two Insulin Detemir Titration Algorithms After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment With or Without Other Anti-diabetic Drugs (OADs)
This trial is conducted in Asia. The aim of the trial is to compare the glycaemic control of
 Levemir® (insulin detemir) administered once daily according to two titration algorithms
 after 20 weeks in subjects with type 2 diabetes inadequately controlled on metformin
 treatment with or without other anti-diabetic drugs (OADs).
Inclusion Criteria:

 -  - Diagnosed with type 2 diabetes mellitus at least 3 months prior to Visit 1 (week -2)

 -  - Treatment with at least 1000 mg metformin per day with/without other OADs at a
 stable dose (at either the maximal tolerated dose or at least half of the maximum
 recommended dose according to the package insert) for at least 3 months prior to Visit
 1

 -  - Insulin-naïve subjects

 -  - HbA1c above or equal to 7.5% by central laboratory analysis

 -  - Body mass index (BMI) below or equal to 35.0 kg/m^2

 Exclusion Criteria:

 -  - Female who is breast-feeding

 -  - The receipt of any investigational product within 4 weeks prior to Visit 1

 -  - Any contraindication to insulin detemir according to the domestic labelling

 -  - Anticipated change of dose of any systemic treatment with products, which in the
 investigator's opinion could interfere with glucose metabolism (such as systemic
 corticosteroids, beta-blockers, monoamine oxidase [MAO] inhibitors)

 -  - Clinically significant diseases which, in the investigator's opinion, may confound
 the results of the trial or pose additional risk in administering trial product

 -  - Any conditions that the investigator judges would interfere with trial participation
 or evaluation of the results